Can-Fite BioPharma Ltd. CANF
Can-Fite BioPharma Ltd. (NYSE: CANF) is an oncology drug developer. Its lead program, Namodenoson (CF102), is in Phase 3 for Advanced hepatocellular carcinoma (Child-Pugh B7). Its next catalyst on record is Piclidenoson: Initiation of Lowe syndrome Phase 2 (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Piclidenoson — Initiation of Lowe syndrome Phase 2 (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Namodenoson (CF102) | Advanced hepatocellular carcinoma (LIVERATION) | small molecule | Phase 3 |
| Piclidenoson (CF101) | Psoriasis (COMFORT) | small molecule | Phase 3 |
| Namodenoson (CF102) | MASH | small molecule | Phase 2 |
| Namodenoson (CF102) | Pancreatic cancer | small molecule | Phase 2 |
| Piclidenoson (CF101) | Lowe syndrome | small molecule | Pre-clinical |
| CF602 | Erectile dysfunction | small molecule | Pre-clinical |
Recent results and decisions
- Aug 3, 2026submitted Phase 2 protocol (5 adult patients, open-label) submitted to Bambino Gesu Children’s Hospital, Rome; not an FDA/EMA filing and no patient dosed yet.
today announced the submission of a Phase 2 clinical study protocol to Bambino Gesù Children’s Hospital in Rome, Italy, for the first clinical evaluation of Piclidenoson in patients with Lowe syndrome
Filing - Jul 6, 2026completed enrollment Enrollment of the first 247 patients completed in the pivotal Phase 3 psoriasis study, reaching the pre-specified interim analysis stage.
today announced completion of enrolment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis.
Filing - Apr 30, 2026positive Phase 2a showed stable disease in >30% of evaluable patients, 35% remain on therapy, one beyond 16 months; favorable safety.
The data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable disease stabilization in a heavily pretreated patient population, in addition to the previously reported favorable safety profile.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.